30 patient drug sensitivity data figure s1. figure s2a myeloid regulator enrichment in aml
TRANSCRIPT
![Page 1: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/1.jpg)
30 patient drug sensitivity data
Figure S1
![Page 2: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/2.jpg)
Figure S2AMyeloid regulator enrichment in AML
![Page 3: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/3.jpg)
Figure S2BMyeloid regulator enrichment in cALL
![Page 4: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/4.jpg)
Figure S2CMyeloid regulator enrichment in CLL
![Page 5: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/5.jpg)
Figure S2DMyeloid regulator enrichment in MDS
![Page 6: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/6.jpg)
Figure S3AMalacards AML
![Page 7: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/7.jpg)
Figure S3BMalacards cALL
![Page 8: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/8.jpg)
Figure S3CMalacards CLL
![Page 9: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/9.jpg)
Figure S3DMalacards MDS
![Page 10: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/10.jpg)
Figure S4ACGC AML
![Page 11: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/11.jpg)
Figure S4BCGC cALL
![Page 12: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/12.jpg)
Figure S4CCGC CLL
![Page 13: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/13.jpg)
Figure S4DCGC MDS
![Page 14: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/14.jpg)
Figure S5
![Page 15: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/15.jpg)
Figure S6
![Page 16: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/16.jpg)
Figure S7
![Page 17: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/17.jpg)
Figure S8Apoptosis AML
![Page 18: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/18.jpg)
Signal transduction
Immune response
Mitochondrial function
Celluar cytoskeletonHeme biosynthesis
Figure S9
![Page 19: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/19.jpg)
BCL-2
BAX
Known anti-apoptotic factors
A key mitochondrial pro-apoptotic protein
Ohtsuka et al (2004)
PYCARD Apoptosis SER in AML
A key mediator in apoptosis and inflammation
Youle et al (2008)
FIGURE S10
![Page 20: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/20.jpg)
Figure S11
![Page 21: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/21.jpg)
Figure S12
![Page 22: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/22.jpg)
Figure S13
![Page 23: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML](https://reader034.vdocument.in/reader034/viewer/2022051820/5697bf711a28abf838c7dd40/html5/thumbnails/23.jpg)
Figure S14